New GLP-1 Agonist in Trials: Retatrutide's Potential Impact | Retatrutide News

Retatrutide, a new GLP-1 agonist, is undergoing clinical trials as part of Eli Lilly's metabolic pipeline. The trials aim to explore its potential for e...
Clinical Trials · October 22, 2026